B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

TRPM8

MOLECULAR TARGET

transient receptor potential cation channel subfamily M member 8

UniProt: Q7Z2W7NCBI Gene: 7905415 compounds

TRPM8 (transient receptor potential cation channel subfamily M member 8) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TRPM8

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1dronabinol4.5392
2eugenol4.0355
3capsazepine3.5634
4cannabigerol2.7114
5cannabidivarin2.5612
6cannabichromene2.4811
7levomenthol2.309
8tetrahydrocannabivarin2.208
9delta9 tetrahydrocannabinolic acid a2.087
10sb 7054982.087
11Menthol1.956
12cbd1.102
13cannabidiol1.102
14Clotrimazole0.691
15Econazole0.691

About TRPM8 as a Drug Target

TRPM8 (transient receptor potential cation channel subfamily M member 8) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented TRPM8 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TRPM8 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.